Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer

Lin,Maosong; Huang,Junxing; Zhu,Jiayi; Shen,Hongzhang

doi:10.3892/etm.2013.1350

Elevated pre‑treatment levels of high sensitivity C‑reactive protein as a potential prognosticator in patients with colorectal cancer

Authors:
- Maosong Lin
- Junxing Huang
- Jiayi Zhu
- Hongzhang Shen
View Affiliations

Affiliations: Department of Gastroenterology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, P.R. China, Department of Oncology, Taizhou People's Hospital, Taizhou, Jiangsu 225300, P.R. China
Published online on: October 16, 2013 https://doi.org/10.3892/etm.2013.1350
Pages: 1369-1374

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Elevated levels of C‑reactive protein (CRP) have been described as a prognostic factor in various types of human malignancy. In the present study, the prognostic potency of CRP was validated for patients with colorectal cancer (CRC) in order to guide patient management and define high‑risk populations for follow‑up or for therapeutic purposes. The association between the high sensitivity‑CRP (hs‑CRP) levels of a total of 123 patients with CRC and their clinicopathological characteristics was explored. Subsequently, univariate and multivariate analyses were performed to investigate the survival impact of pre‑treatment hs‑CRP levels in this cohort study. Statistically significant correlations between the serum levels of hs‑CRP and lymph node and distant metastasis (P<0.001 and P=0.012, respectively), vascular and perineural invasion (P<0.001 and P<0.001), grades (P=0.022) and clinical stages (P=0.001), but not age and gender (P=0.616 and 0.676, respectively), were found. The five‑year survival rate of patients with elevated (>5.0 mg/l) hs‑CRP levels was demonstrated to be significantly less than that of those in the normal group (≤5.0 mg/l) by applying the Kaplan‑Meier method (13.3 versus 57.0%, log‑rank test P<0.001). Furthermore, following identification as a prognostic factor through using univariate analysis, high levels of hs‑CRP (P<0.001) were validated as an independent prognosticator in CRC in the present study through using multivariate analysis. Pre‑treatment serum CRP levels were associated with advanced and progressed CRC patients, therefore these levels may serve as a potential prognostic marker for CRC patients.

View Figures

View References

1	American Cancer Society. Cancer Facts and Figures. 2010
2	Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MM and Song JM: The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol. 21(Suppl 1): 48–50. 1992.PubMed/NCBI
3	Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD and Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 52:594–601. 1998.PubMed/NCBI
4	Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T and Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol. 174:2120–2123. 2005. View Article : Google Scholar
5	Onitilo AA, Engel JM, Greenlee RT and Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 7:4–13. 2009. View Article : Google Scholar
6	Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R and Quirke P: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 29:1261–1270. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tillett WS and Francis T: Serological reaction in pneumonia with a non-protein somatic fraction of pnemoncoccus. J Exp Med. 52:561–571. 1930. View Article : Google Scholar : PubMed/NCBI
8	Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R and Heinrich PC: Acute-phase response of human hepatocytes; regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 12:1179–1186. 1990. View Article : Google Scholar : PubMed/NCBI
9	Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD and Harken AH: Diagnostic implications of C.reactive protein. Arch Surg. 138:220–224. 2003. View Article : Google Scholar : PubMed/NCBI
10	Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A and Sudo A: Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 15:1055–1061. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY and Kim HJ: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 9:1552009. View Article : Google Scholar : PubMed/NCBI
12	Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, Zheng YL, Bowman ED, Engels EA, Caporaso NE and Harris CC: Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 103:1112–1122. 2011. View Article : Google Scholar : PubMed/NCBI
13	Lee S, Choe JW, Kim HK and Sung J: High-sensitivity C-reactive protein and cancer. J Epidemiol. 21:161–168. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB and Reinthaller A: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 14:710–714. 2008. View Article : Google Scholar : PubMed/NCBI
15	Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ and Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastrooesophageal cancer. Br J Cancer. 94:1568–1571. 2006.
16	Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M and Sata M: Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 27:1091–1097. 2007. View Article : Google Scholar : PubMed/NCBI
17	Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A and Hefler LA: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol. 107:114–117. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ishizuka M, Nagata H, Takagi K and Kubota K: C-reactive protein is associated with distant metastasis of T3 colorectal cancer. Anticancer Res. 32:1409–1415. 2012.PubMed/NCBI
19	Lee WS, Baek JH, You DH and Nam MJ: Prognostic value of circulating cytokines for stage III colon cancer. J Surg Res. 182:49–54. 2012.PubMed/NCBI
20	Lin MS, Huang JX, Zhu JY and Shen HZ: Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology. 59:1687–1690. 2012.PubMed/NCBI
21	Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y and Kihara K: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 100:269–273. 2007. View Article : Google Scholar
22	Stein B, Schrader AJ, Wegener G, Seidel C, Kuczyk MA and Steffens S: Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer. 13:101–105. 2013. View Article : Google Scholar : PubMed/NCBI
23	Hussain SP and Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 121:2373–2380. 2007. View Article : Google Scholar : PubMed/NCBI
24	Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 49:347–353. 2001. View Article : Google Scholar
25	Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
26	Jess T, Gamborg M, Matzen P, Munkholm P and Sørensen TI: Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of populationbased cohort studies. Am J Gastroenterol. 100:2724–2729. 2005.
27	Kushner I, Rzewnicki D and Damols D: What does minor elevation of C-reactive protein signify? Am J Med. 119:166.e17–e28. 2006. View Article : Google Scholar : PubMed/NCBI
28	Heikkilä K, Ebrahim S and Lawlor DA: A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 61:824–833. 2007.PubMed/NCBI
29	Nozoe T, Saeki H and Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 182:197–201. 2001. View Article : Google Scholar : PubMed/NCBI
30	Sanjay P, de Figueiredo RS, Leaver H, Ogston S, Kulli C, Polignano FM and Tait IS: Preoperative serum C-reactive proteinlevels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP. 13:199–204. 2012.
31	Slaviero KA, Clarke SJ and Rivory LP: Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 4:224–232. 2003.PubMed/NCBI
32	Erlinger TP, Platz EA, Rifai N and Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA. 291:585–590. 2004. View Article : Google Scholar : PubMed/NCBI
33	Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D and Sinha R: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 66:2483–2487. 2006. View Article : Google Scholar : PubMed/NCBI
34	Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S and Kritchevsky SB: Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 14:2413–2418. 2005.PubMed/NCBI
35	Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M, Ozasa K, Watanabe Y, Kawado M, Hashimoto S, Suzuki S, Tokudome S, Toyoshima H, Hayakawa N, Kato K, Watanabe M, Ohta Y, Maruta M and Tamakoshi A; JACC Study Group. Colorectal cancer and serum C-reactive protein levels: a case control study nested in the JACC Study. J Epidemiol. 15(Suppl 2): S185–S189. 2005. View Article : Google Scholar : PubMed/NCBI
36	Otani T, Iwasaki M, Sasazuki S, Inoue M and Tsugane S: Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev. 15:690–695. 2006. View Article : Google Scholar
37	Siemes C, Visser LE, Coebergh JW, et al: C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 24:5216–5222. 2006. View Article : Google Scholar : PubMed/NCBI
38	Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A and Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 15:381–384. 2006. View Article : Google Scholar : PubMed/NCBI
39	Zhang SM, Buring JE, Lee IM, Cook NR and Ridker PM: C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med. 142:425–432. 2005. View Article : Google Scholar : PubMed/NCBI
40	Ognjanovic S, Yamamoto J, Saltzman B, Franke A, Ognjanovic M, Yokochi L, Vogt T, Decker R and Le Marchand L: Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes Control. 21:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI
41	Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP and Platz EA: C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 123:1133–1140. 2008. View Article : Google Scholar : PubMed/NCBI
42	Guo YZ, Pan L, Du CJ, Ren DQ and Xie XM: Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pacific J Cancer Prev. 14:243–248. 2013. View Article : Google Scholar : PubMed/NCBI
43	Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D and Sinha R: A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 66:2483–2487. 2006. View Article : Google Scholar : PubMed/NCBI
44	Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M and Hölscher AH: Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 20:231–238. 2009. View Article : Google Scholar : PubMed/NCBI
45	D’Angelo E, Espinosa I, Ali R, Gilks CB, Rijn M, Lee CH and Prat J: Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol. 121:328–333. 2011.PubMed/NCBI
46	Ma J, Liu L, Tang L, Zong J, Lin A, Lu T, Cui N, Cui C and Li L: Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 13:1445–1452. 2007. View Article : Google Scholar : PubMed/NCBI
47	Zacharakis M, Xynos ID, Lazaris A, Smaro T, Kosmas C, Dokou A, Felekouras E, Efstathios A, Polyzos A, Sarantonis J, Syrios J, Zografos G, Papalambros A and Tsavaris N: Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res. 30:653–660. 2010.PubMed/NCBI
48	McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 90:215–219. 2003. View Article : Google Scholar
49	Siemes C, Visser LE, Coebergh JW, Splinter TAW, Witteman JCM, Uitterlinden AG, Hofman A, Pols HAP and Stricker BH: C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 24:5216–5222. 2006. View Article : Google Scholar : PubMed/NCBI
50	Ramsey S, Lamb GWA, Aitchison M and McMillan DC: The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer. Br J Cancer. 95:1076–1080. 2006. View Article : Google Scholar
51	Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y and Sugimachi K: Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus-significance as a tumor marker. Cancer Lett. 192:89–95. 2003. View Article : Google Scholar : PubMed/NCBI
52	Rutkowski P, Kaminska J, Kowalska M, Ruka W and Steffen J: Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer. 100:463–471. 2002. View Article : Google Scholar : PubMed/NCBI
53	Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ and Ross JA: Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 21:881–886. 2002.